NeuroTherapia Raises $123M in First Close of Series B Funding

NeuroTherapia's Funding Announcement

NeuroTherapia Inc., a clinical-stage biotech company, has announced the first close of its Series B financing round, raising $123 million.

Phase 2a Clinical Trial

NeuroTherapia will utilize the funds to advance its Phase 2a clinical trial for NTRX-07, a novel therapeutic for neurodegenerative diseases.

Cleveland Clinic Innovations Partnership

NeuroTherapia, a portfolio company of Cleveland Clinic Innovations, is focused on developing innovative treatments for neurodegenerative diseases.